Tag Archives: FDA

PANTHERx Rare selected by Xeris Pharmaceuticals as Exclusive Distributor of Recorlev

PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).

Veru, Inc. Marketing ENTADFI Through GoodRx and Internal Telepharmacy Platform

ENTADFI will be marketed and distributed through Veru’s own telemedicine and telepharmacy services platform as well as through a partnership with GoodRx

Biologics by McKesson Starting the New Year With Momentum

Biologics by McKesson, selected as a specialty pharmacy distributor for three specialty drugs recently, is starting the new year with momentum

Amber Specialty Pharmacy Selected by Takeda to Dispense LIVTENCITY™

Amber Specialty Pharmacy announced that it will begin dispensing LIVTENCITY™ (maribavir), the first and only treatment indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease

Aetna Launches New Network to Cover New Gene Therapies for Rare Diseases

Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies

AllianceRx Walgreens Prime Dispensing Arcalyst and Gavreto

AllianceRx Walgreens Prime (AllianceRx) is offering Arcalyst (rilonacept) and Gavreto (pralsetinib), two medicines prescribed for the treatment of specific kinds of cancer as well as an autoinflammatory cardiovascular disease

Soleo Health Extending Specialty Infusion Leadership Position

Soleo Health’s care model and related services add value for patients with complex conditions, including rare and ultra-rare diseases

GBT’s Oxbryta® Accepted by FDA for Priority Review for Pediatric Sickle Cell Disease

The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for voxelotor (Oxbryta®) for the treatment of sickle cell disease in patients aged 4 to 11 years